[Edaily Reporter SOYEON KIM ] SK hynix announced on the 7th that, following a board resolution, it has decided to invest a total of 54 trillion won—35.2 trillion won in the construction of its second-phase fab in Yongin and 19.1 trillion won in the construction of the “M17” fab in Cheongju.
This week (August 31–September 4), startups across various sectors—including virtual intellectual property (IP), freight transportation, social apps, and space technology—secured investments from vent…
SK BIOPHARMACEUTICALS(326030)is attributing significance beyond that of a mere follow-up pipeline to Opakalim (BHV-7000), a new epilepsy drug candidate it acquired from the U.S.-based Biohaven. It is …
South Korea’s pharmaceutical and biotech sector experienced significant volatility on August 13, driven by growth themes in obesity/medical aesthetics, hair loss, and immuno-oncology. #GCWellbeing sur…
